Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel

被引：0

作者：

Shibuki, Taro ^{[1
,2
]}

Otsuka, Taiga ^{[3
,4
]}

Shimokawa, Mototsugu ^{[5
,6
]}

Nakazawa, Junichi ^{[7
]}

Arima, Shiho ^{[8
]}

Fukahori, Masaru ^{[9
,10
]}

Miwa, Keisuke ^{[11
]}

Okabe, Yoshinobu ^{[9
]}

Koga, Futa ^{[12
]}

Ueda, Yujiro ^{[13
]}

Kubotsu, Yoshihito ^{[14
]}

Makiyama, Akitaka ^{[15
,16
]}

Shimokawa, Hozumi ^{[15
]}

Takeshita, Shigeyuki ^{[17
]}

Nishikawa, Kazuo ^{[18
]}

Komori, Azusa ^{[18
,19
]}

Otsu, Satoshi ^{[18
]}

Hosokawa, Ayumu ^{[20
]}

Sakai, Tatsunori ^{[21
]}

Oda, Hisanobu ^{[22
]}

Kawahira, Machiko ^{[23
]}

Arita, Shuji ^{[24
]}

Honda, Takuya ^{[25
]}

Taguchi, Hiroki ^{[7
,26
]}

Tsuneyoshi, Kengo ^{[27
]}

Kawaguchi, Yasunori ^{[28
]}

Fujita, Toshihiro ^{[26
]}

Sakae, Takahiro ^{[26
]}

Nio, Kenta ^{[29
,30
]}

Ide, Yasushi ^{[14
,31
]}

Ureshino, Norio ^{[3
,32
]}

Shirakawa, Tsuyoshi ^{[33
,34
]}

Mizuta, Toshihiko ^{[35
]}

Mitsugi, Kenji ^{[29
,30
]}

机构：

[1] Natl Canc Ctr Hosp East, Dept Promot Drug & Diagnost Dev, Div Drug & Diagnost Dev Promot, Translat Res Support Off, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan

[2] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan

[3] Saga Ken Med Ctr Koseikan, Dept Med Oncol, 400 Kase Machi, Saga, Saga 8408571, Japan

[4] Minato Med Clin, Dept Internal Med, 3-11-3 Nagahama,Chuo Ku, Fukuoka, Fukuoka 8100072, Japan

[5] Natl Kyushu Canc Ctr, Clin Res Inst, 3-1-1 Notame,Minami Ku, Fukuoka, Fukuoka 8111395, Japan

[6] Yamaguchi Univ, Grad Sch Med, Dept Biostat, 1-1-1 Minamikogushi, Ube, Yamaguchi 7558505, Japan

[7] Kagoshima City Hosp, Dept Gastroenterol, 37-1 Uearata Cho, Kagoshima, Kagoshima 8908760, Japan

[8] Kagoshima Univ, Grad Sch Med & Dent Sci, Digest & Lifestyle Dis, 8-35-1 Sakuragaoka, Kagoshima, Kagoshima 8908520, Japan

[9] Kurume Univ, Dept Med, Div Gastroenterol, Sch Med, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan

[10] Kyoto Univ Hosp, Kyoto Innovat Ctr Next Generat Clin Trials & iPS C, 54 Kawaharacho,Shogoin,Sakyo Ku, Kyoto 6068507, Japan

[11] Kurume Univ Hosp, Multidisciplinary Treatment Canc Ctr, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan

[12] Saga Med Ctr Koseikan, Dept Hepatobiliary & Pancreatol, 400 Kase Machi, Saga, Saga 8408571, Japan

[13] Japanese Red Cross Kumamoto Hosp, Dept Hematol & Oncol, 2-1-1 Nagamine-Minami,Higashi Ku, Kumamoto, Kumamoto 8618520, Japan

[14] Karatsu Red Cross Hosp, Dept Internal Med, 2430 Watada, Karatsu, Saga 8478588, Japan

[15] Japan Community Healthcare Org Kyushu Hosp, Dept Hematol Oncol, 1-8-1 Kishinoura,Yahatanishi Ku, Kitakyushu, Fukuoka 8068501, Japan

[16] Gifu Univ Hosp, Canc Ctr, 1-1 Yanagido, Gifu 5011194, Japan

[17] Japanese Red Cross Nagasaki Genbaku Hosp, Dept Gastroenterol, 3-15 Morimachi, Nagasaki, Nagasaki 8528511, Japan

[18] Oita Univ, Fac Med, Dept Med Oncol & Hematol, 1-1 Idaigaoka,Hasama Machi, Yufu, Oita 8795593, Japan

[19] Natl Hosp Org Shikoku Canc Ctr, Dept Gastrointestinal Med Oncol, 160 Minamiumemoto Cho, Matsuyama, Ehime 7910280, Japan

[20] Univ Miyazaki Hosp, Dept Clin Oncol, 5200 Kihara, Kiyotake, Miyazaki 8891692, Japan

[21] Natl Hosp Org Kumamoto Med Ctr, Dept Med Oncol, 1-5 Ninomaru,Chuo Ku, Kumamoto, Kumamoto 8600008, Japan

[22] Saiseikai Kumamoto Hosp, Div Integrat Med Oncol, 5-3-1 Oumi,Minami Ku, Kmamoto, Kumamoto 8614193, Japan

[23] Kagoshima Kouseiren Hosp, Dept Gastroenterol, 1-13-1 Yojirou, Kagoshima, Kagoshima 8900062, Japan

[24] Miyazaki Prefectural Miyazaki Hosp, Dept Chemotherapy, Miyazaki, Japan

[25] Nagasaki Univ, Grad Sch Biomed Sci, Dept Gastroenterol & Hepatol, 1-7-1 Sakamoto, Nagasaki, Nagasaki 8528501, Japan

[26] Saiseikai Sendai Hosp, Dept Gastroenterol, 2-46 Harada Cho, Satsumasendai, Kagoshima 8950074, Japan

[27] Izumi Gen Med Ctr, Dept Gastroenterol, 520 Myoujin Cho, Izumi, Kagoshima 8990131, Japan

[28] Asakura Med Assoc Hosp, Dept Gastroenterol, 422-1 Raiha, Asakura, Fukuoka 8380069, Japan

[29] Sasebo Kyosai Hosp, Dept Med Oncol, 10-17 Shimanji Cho, Sasebo, Nagasaki 8578575, Japan

[30] Hamanomachi Hosp, Dept Med Oncol, 3-3-1 Nagahama,Chuo Ku, Fukuoka, Fukuoka 8108539, Japan

[31] Natl Hosp Org Saga Hosp, Dept Internal Med, 1-20-1 Hinode, Saga, Saga 8498577, Japan

[32] Kimitsu Chuo Hosp, Dept Med Oncol, 1010 Sakurai, Kisarazu, Chiba 2928535, Japan

[33] Eikoh Hosp, 3-8-15 Befu Nishi,Shime Machi, Fukuoka 8112232, Japan

[34] Clin Hematol Oncol Treatment Study Grp, 1-14-6 Muromi Gaoka,Nishi Ku, Fukuoka, Fukuoka 8190030, Japan

[35] Fujikawa Hosp, Dept Internal Med, 1-2-6 Matsubara, Saga, Saga 8400831, Japan

来源：

SCIENTIFIC REPORTS | 2024年 / 14卷 / 01期

关键词：

Pancreatic cancer; Second line; Nanoliposomal irinotecan; S-1; FOLFIRINOX; RANDOMIZED PHASE-II; C-REACTIVE PROTEIN; NAB-PACLITAXEL; 1ST-LINE CHEMOTHERAPY; PLUS GEMCITABINE; SURVIVAL; PROGNOSIS; TRIAL;

D O I：

10.1038/s41598-024-65689-8

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

This study aimed to compare second-line treatment outcomes for patients with unresectable pancreatic cancer previously treated with gemcitabine plus nab-paclitaxel (GnP) therapy. We conducted an integrated analysis of two retrospective studies included 318 patients receiving nanoliposomal irinotecan + 5-fluorouracil/folinic acid (NFF) (n = 102), S-1 (n = 57), or FOLFIRINOX (n = 14) as second-line treatment. Median overall survival (OS) in the NFF group was 9.08 months, significantly better than S-1 (4.90 months, P = 0.002). FOLFIRINOX had a median OS of 4.77 months, not statistically different from NFF. Subgroup analyses of OS indicated NFF was generally superior, however, a statistical interaction was observed between the treatment regimen in serum Alb < 3.5 g/dL (P = 0.042) and serum CRP >= 0.3 mg/dL (P = 0.006). Median progression-free survival (PFS) was 2.93 months for NFF, significantly better than S-1 (2.53 months, P = 0.024), while FOLFIRINOX had a comparable PFS (3.04 months, P = 0.948). Multivariate analysis identified the serum CRP, serum CA19-9, duration of first-line GnP therapy, and use (yes/no) of S-1 for second-line treatment as independent predictors for OS. This study concludes that second-line NFF therapy demonstrated a more favorable OS compared to S-1 therapy, however, it is still important to consider the patient background characteristics while selecting the most appropriate treatment.

引用

页数：10

共 50 条

[21] Exceptional Response to Second-Line Gemcitabine/Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma
Bukhari, Nedal
Abdalla, Khalda
Ibnshamsa, Fahad
Alselwi, Waleed
Al-Shakir, Shakir
Alqahtani, Mohammed
CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (10)
[22] FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study
Cho, In Rae
Kang, Huapyong
Jo, Jung Hyun
Lee, Hee Seung
Chung, Moon Jae
Park, Jeong Youp
Park, Seung Woo
Song, Si Young
An, Chansik
Park, Mi-Suk
Bang, Seungmin
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2020, 12 (02) : 182 - 194
[23] Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients
Merz, Valeria
Cavaliere, Alessandro
Messina, Carlo
Salati, Massimiliano
Zecchetto, Camilla
Casalino, Simona
Milella, Michele
Caffo, Orazio
Melisi, Davide
CANCERS, 2020, 12 (05)
[24] S-1 Monotherapy as Second-line Treatment for Advanced Pancreatic Cancer after Gemcitabine Failure
Todaka, Akiko
Fukutomi, Akira
Boku, Narikazu
Onozawa, Yusuke
Hironaka, Shuichi
Yasui, Hirofumi
Yamazaki, Kentaro
Taku, Keisei
Machida, Nozomu
Sakamoto, Takeshi
Tomita, Hideharu
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (06) : 567 - 572
[25] Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
Vogl, Ursula M.
Andalibi, Haleh
Klaus, Alexander
Vormittag, Laurenz
Schima, Wolfgang
Heinrich, Bettina
Kafka, Alice
Winkler, Thomas
Ohler, Leopold
BMC CANCER, 2019, 19 (1)
[26] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer: a multicenter, randomized, phase II study
Jin, Min
Liu, Hong-Li
Xue, Jun
Ma, Hong
Liu, Jun-Li
Lin, Zhen-Yu
Wang, Jing
Bao, Le-Qun
Luo, Zhi-Guo
Yu, Xiong-Jie
Li, Shuang
Hu, Jian-Li
Zhang, Tao
ONCOLOGIST, 2024, 29 (10): : e1406 - e1418
[27] Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis
Riedl, Jakob M.
Posch, Florian
Horvath, Lena
Gantschnigg, Antonia
Renneberg, Felix
Schwarzenbacher, Esther
Moik, Florian
Barth, Dominik A.
Rossmann, Christopher H.
Stotz, Michael
Schaberl-Moser, Renate
Pichler, Martin
Stoger, Herbert
Greil, Richard
Djanani, Angela
Schlick, Konstantin
Gerger, Armin
EUROPEAN JOURNAL OF CANCER, 2021, 151 : 3 - 13
[28] Successful Treatment with Nab-Paclitaxel and Gemcitabine after FOLFIRINOX Failure in a Patient with Metastasized Pancreatic Adenocarcinoma
Berger, Anne K.
Weber, Tim F.
Jaeger, Dirk
Springfeld, Christoph
ONKOLOGIE, 2013, 36 (12): : 763 - 765
[29] A phase-I study of second-line S-IROX for unresectable pancreatic cancer after gemcitabine plus nab-paclitaxel failure
Okuno, Mitsuru
Mukai, Tsuyoshi
Iwata, Keisuke
Takagi, Akihiro
Ito, Yuki
Ohashi, Yosuke
Tezuka, Ryuichi
Iwasa, Yuhei
Iwata, Shota
Tomita, Eiichi
MEDICAL ONCOLOGY, 2024, 41 (08)
[30] Baseline Factors Predictive of the Receipt of Second-Line Chemotherapy After Nab-Paclitaxel Plus Gemcitabine for Patients With Advanced Pancreatic Cancer
Iede, Kiyotsugu
Yamada, Terumasa
Koh, Masahiro
Ueda, Masami
Tsuda, Yujiro
Nakashima, Shinsuke
Ohta, Katsuya
Tanida, Tsukasa
Matsuyama, Jin
Ikenaga, Masakazu
Tominaga, Shusei
PANCREAS, 2022, 51 (03) : 278 - 281

← 1 2 3 4 5 →